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Pharmacological Unmasking Microarray Approach-Based 
Discovery of Novel DNA Methylation Markers for Hepatocellular 
Carcinoma 
DNA methylation is one of the main epigenetic mechanisms and hypermethylation of CpG 
islands at tumor suppressor genes switches off these genes. To find novel DNA methylation 
markers in hepatocellular carcinoma (HCC), we performed pharmacological unmasking 
(treatment with 5-aza-2´-deoxycytidine or trichostatin A) followed by microarray analysis 
in HCC cell lines. Of the 239 promoter CpG island loci hypermethylated in HCC cell lines  
(as revealed by methylation-specific PCR), 221 loci were found to be hypermethylated in 
HCC or nonneoplastic liver tissues. Thirty-three loci showed a 20% higher methylation 
frequency in tumors than in adjacent nonneoplastic tissues. Correlation of individual 
cancer-related methylation markers with clinicopathological features of HCC patients 
(n = 95) revealed that the number of hypermethylated genes in HCC tumors was higher in 
older than in younger patients. Univariate and multivariate survival analysis revealed that 
the HIST1H2AE methylation status is closely correlated with the patient’s overall survival 
(P = 0.022 and P = 0.010, respectively). In conclusion, we identified 221 novel DNA 
methylation markers for HCC. One promising prognostic marker, HIST1H2AE, should be 
further validated in the prognostication of HCC patients.
Key Words: CpG Islands; DNA Methylation; Carcinoma, Hepatocellular; Microarray; 
Prognosis
Namhee Jung
1, Jae Kyung Won
2, 
Baek-Hui Kim
3, Kyung Suk Suh
4, 
Ja-June Jang
2, and Gyeong Hoon Kang
1,2
1Laboratory of Epigenetics, Cancer Research 
Institute, 
2Departments of Pathology, 
3General 
Surgery, Seoul National University College of 
Medicine, Seoul; 
4Department of Pathology, Korea 
University School of Medicine, Seoul, Korea
Received: 21 November 2011
Accepted: 23 February 2012
Address for Correspondence:
Gyeong Hoon Kang, MD
Department of Pathology, Seoul National University College of 
Medicine, 103 Daehak-ro, Jongno-gu, Seoul 110-799, Korea
Tel: +82.2-740-8263, Fax: +82.2-743-5530
E-mail: ghkang@snu.ac.kr
This study was supported by a Mid-career Researcher Program 
through NRF grant funded by the Ministry of Education, Science 
and Technology (MEST) (2011-0015646) and a Priority Research 
Centers Program through the National Research Foundation of 
Korea (NRF) funded by MEST (2009-0093820).
http://dx.doi.org/10.3346/jkms.2012.27.6.594  •  J Korean Med Sci 2012; 27: 594-604
ORIGINAL ARTICLE
Oncology & Hematology
INTRODUCTION
CpG islands are CpG dinucleotide-rich areas found within the 
promoter and 5´ exonic regions of about 60%-70% of the human 
genes (1, 2). Aberrant hypermethylation on promoter CpG island 
loci can lead to inactivation of genes that are actively expressed 
or increased silencing of genes that are inactive. While both ge-
netic mutations and promoter CpG island hypermethylation 
changes are simultaneously found in human cancer cells, re-
cent studies have demonstrated that the number of genes inac-
tivated by promoter CpG island hypermethylation is four-times 
higher than the number of genes undergoing mutations in colorec-
tal cancers (3, 4). Besides its importance as a gene inactivation 
mechanism, promoter CpG island hypermethylation is gaining 
attention as a potential tumor biomarker. In this respect, DNA 
methylation markers are being actively investigated to detect 
human cancers in blood, secretions, or exfoliated cytology spec-
imens, and to predict the risk of cancer progression and devel-
opment (5-9).
  Primary liver cancer is the fifth most common cancer world-
wide and the third most common cause of death by cancer (10, 
11). The overall incidence and mortality of hepatocellular carci-
noma (HCC) has been decreasing in areas with high incidence 
(12). However, both the incidence and mortality rates of HCC 
are increasing in Western countries (13). The development of 
HCC is the consequence of a multistep process that involves 
several morphologically recognizable lesions and accumula-
tion of molecular changes at the genetic and epigenetic levels. 
Several studies have reported HCC-associated genetic changes, 
including mutations in several tumor suppressor genes (TP53, 
p16, PTEN, IGF2R, and RB), oncogenes (c-MYC, c-MET, PIK3CA, 
and CTNNB1), and other cancer-associated genes (CDH1 and 
CCND1) (14, 15). Not only genetic changes but also epigenetic 
alterations underlie the evolution of HCC. Since hypermethyl-
ation of the CDH1 promoter CpG island locus was reported in 
HCC (16), about 150 other genes have been found to be hyper-
methylated in HCC in a cancer-specific manner (17-19). How-
ever, more genes undergoing hypermethylation of promoter 
CpG island loci are likely to be identified in HCC. Schuebel and 
colleagues reported that about 400 genes actively expressed in 
normal colon epithelial cells are inactivated by promoter CpG 
island hypermethylation in colorectal cancers (3). Jung N, et al.  •  Novel DNA Methylation Markers for Hepatocellular Carcinoma
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  Of the increasingly higher number of genes being identified 
as undergoing promoter CpG island hypermethylation in HCC, 
only a few have clinical relevance and potential utility as bio-
markers for prediction of recurrence or poor prognosis (20-23). 
The primary aim of the present study is to discover novel can-
cer-related DNA methylation markers for HCC. We performed 
a large-scale gene expression microarray analysis, which enables 
the simultaneous characterization of the transcription profile of 
tens of thousands of genes, on HCC cell lines treated with de-
methylating agents. Of the genes up-regulated by treatment with 
demethylating agents, we selected those harboring CpG island 
loci in their promoter sequences. We then performed methyla-
tion-specific PCR (MSP) to determine whether promoter CpG 
island loci of the candidate genes were hypermethylated in HCC 
and whether this modification was cancer-specific. We found 2 
promising cancer-specific methylated genes (HIST1H2AE and 
EFEMP2) that are associated with poor prognosis in patients 
with HCC.
 
MATERIALS AND METHODS
Cell line culture and 5-aza-2´-deoxycytidine (AZA) treatment
A total of 8 HCC cell lines (SNU398, SNU475, SNU739, SNU761, 
SNU878, SNU886, HepG2, and Huh7) were obtained from the 
Korean Cell Line Bank (Seoul, Korea). All cell lines were main-
tained in RPMI-1640 medium with the exception of Huh7, 
which was maintained in Dulbecco’s modified Eagle’s medium 
(DMEM). HEPES buffer (25 mM), fetal bovine serum (FBS) 
(10%), penicillin (100 units/mL), and streptomycin (0.1 mg/mL) 
were added to the medium. We seeded 3 × 10
5 cells (from each 
of the cell lines) per milliliter of culture medium and treated 
them 24 hr later with 5 μM AZA (Sigma Chemical Co., St. Louis, 
MO, USA) for 96 hr, during which period media and drugs were 
changed every 24 hr. AZA was dissolved in acetic acid and diluted 
to 10 mg/mL. Cells were incubated for 72 hr and then treated 
with trichostatin A (TSA; Sigma) at 300 nM for 24 hr. For co-treat-
ment of cells with AZA and TSA, AZA (5 μM) was added initially 
for 72 hr, after which it was removed, and AZA (5 μM) and TSA 
(300 nM) were added for an additional 24 hr. As a negative con-
trol, cell lines were treated with acetic acid in an equal volume 
of medium without the drug.
Patients and tissue specimens
Formalin-fixed, paraffin-embedded archival tissues from 95 
HCC patients (mean age 55 yr; 75 males and 20 females) were 
retrieved from the files of the Department of Pathology, Seoul 
National University Hospital (Seoul, Korea). These patients had 
undergone curative surgery for HCC from 2001 to 2004 at the 
Seoul National University Hospital. The degree of fibrosis in non-
neoplastic livers was graded according to the Ishak scoring sys-
tem. A liver with a fibrosis staging score of 5 or 6 was considered 
cirrhotic. For histological examination, tissue blocks containing 
tumors were selected and serially sectioned. Nonneoplastic liver 
tissues were obtained  > 3 cm away from tumor regions and con-
firmed to be tumor-free by microscopic examination. We re-
viewed the electronic medical records of the patients to obtain 
clinicopathological information, including age, gender, Child-
Pugh classification, and γ-glutamyltranspeptidase (GGT) and 
alpha-fetoprotein (AFP) levels. Fresh-frozen tissue samples of 
HCC and adjacent nonneoplastic liver were obtained from HCC 
patients (n = 10) who underwent curative resection for HCC at 
the Seoul National University Hospital in 2008. 
 
Microarray
Illumina’s whole-genome expression arrays (Sentrix Human-
Ref-8 Expression BeadChip; Illumina, Inc., San Diego, CA, USA) 
were used to analyze the RNA expression profiles of 5 HCC cell 
lines (SNU 398, SNU 761, SNU 878, HepG2, and Huh7) before 
and after treatment with AZA (5 μM) or TSA (300 nM).
Methylation-specific PCR (MSP)
For methylation analysis, 2 μg of genomic DNA obtained from 
HCC cell lines and tissue samples was modified using the EZ 
DNA Methylation
TM Kit (Zymo Research, Orange, CA, USA) ac-
cording to the manufacturer’s protocol. The specific primers for 
bisulfite modified DNA were designed using MSPPrimer (http: 
//www.mspprimer.org). For genes whose primer sequences 
could not be obtained by using the MSPPrimer software, MSP 
primers were designed using MethPrimer (http://www.urogene. 
org/methprimer). MSP primer sequences are available on re-
quest. MSP was performed as previously described (24).
Reverse transcription (RT)-PCR
We isolated total RNA from 8 HCC cell lines by using the RNeasy 
Mini Kit (Qiagen, Valencia, CA, USA) according to the manu-
facturer’s protocol. A total of 5 μg of RNA was reverse-transcribed 
using Superscript III (Invitrogen, Carlsbad, CA, USA). Semi-quan-
titative real-time PCR was performed with 10 ng of cDNA in a 
7300 Real-Time PCR System (Applied Biosystems, Foster City, 
CA, USA) by using the SYBR
® Green PCR Master Mix (Applied 
Biosystems). Gene expression levels were normalized to the ex-
pression of GAPDH. Oligonucleotide sequences of primers and 
PCR conditions are available on request.
Statistics
Associations between clinicopathological features and hyper-
methylated gene markers were analyzed using SPSS 13.0 for Win-
dows. P values were based on Fisher’s exact test or Pearson’s 
chi-squared test. Survival was measured from the surgical resec-
tion day until death or the last clinical review before August 31, 
2007. Overall survival was estimated by the method of the Ka-
plan-Meier log-rank test, and Cox proportional hazard analysis Jung N, et al.  •  Novel DNA Methylation Markers for Hepatocellular Carcinoma
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was used to estimate multivariate relationships between several 
clinicopathological and hypermethylated gene markers. P < 0.05 
was considered significant.
Ethics statement
This study was approved by the institutional review board of the 
Seoul National University Hospital (Approval No., C-1007-209-
325). Written informed consent was exempted considering the 
retrospective nature of the study and minimal harm to the pa-
tients.
RESULTS
Pharmacological unmasking and microarray analysis in 
HCC cell lines
The expression profiles of 5 HCC cell lines (SNU398, SNU761, 
SNU878, HepG2, and Huh7) were obtained before and after 
treatment with either AZA or TSA by using a microarray plat-
form (Fig. 1). To identify genes undergoing hypermethylation-
dependent expression changes, we determined the expression 
fold changes of individual genes between mock-treated and 
TSA- or AZA-treated cells, and plotted TSA- and AZA-related 
fold changes on the x- and y-axis, respectively (Fig. 2). The DNA 
demethylating agent (AZA) induces reexpression of densely 
hypermethylated and transcriptionally inactive genes, whereas 
the class I and II histone deacetylase inhibitor (TSA) does not 
induce reexpression (25, 26). Of the genes that did not show an 
Fig. 1. Flow chart for selection of candidate genes. Screening of candidate tumor 
suppressor genes (TSGs) was performed in 5 hepatocellular carcinoma (HCC) cell 
lines treated with 5 µM 5-aza-2´-deoxycytidine (AZA) or 300 nM trichostatin A (TSA) 
by using a 24,526-oligonucleotide mRNA microarray. We obtained 793 candidates 
whose gene expression did not increase with TSA treatment (< 1.4-fold) but increased 
more than 2-fold after AZA treatment. We excluded genes that do not harbor CpG is-
lands in their promoters or whose methylation  status in HCC tumors had already been 
reported in the literature. We further excluded genes for which adequate oligonucle-
otide primers could not be designed by using the MSPprimer or MethPrimer software 
programs. As a result, we selected 380 genes to be examined for their methylation 
status in HCC cell lines by using methylation-specific PCR (MSP).
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Fig. 2. Hypermethylation-dependent expression changes. Gene 
expression changes for the indicated cells treated with trichostatin 
A (TSA) (x-axis) or 5-aza-2´-deoxycytidine (AZA) (y-axis) are plot-
ted by log-fold change, and individual genes are shown in circles.Jung N, et al.  •  Novel DNA Methylation Markers for Hepatocellular Carcinoma
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increase in expression with TSA treatment (< 1.4-fold), subsets 
of genes displayed a peak of AZA-induced gene expression (> 2-
fold). We considered the genes showing both  < 1.4-fold expres-
sion with TSA treatment and  > 2-fold expression with AZA treat-
ment as candidate genes that might be inactivated by hyper-
methylation. In at least one of 5 cell lines, 793 genes were found 
to meet the selection criteria. Of these, genes that have no CpG 
islands in their promoters and proximal transcriptional start 
sites (TSS) as well as those genes whose methylation status in 
HCC had already been reported, were excluded from subsequent 
analysis (Fig. 1).
DNA methylation status of candidate genes in HCC cell lines
To identify whether the candidate genes (n = 443) are methyl-
ated in their promoter CpG island loci, we tried to design MSP 
primers by using the MSPprimer or MethPrimer software pro-
grams and successfully designed optimal primers for 380 genes. 
We analyzed the methylation status of these 380 genes in 8 HCC 
cell lines (SNU398, SNU475, SNU739, SNU761, SNU878, SNU886, 
HepG2, and Huh7) using MSP and found that 239 of 380 genes 
were methylated in one or more cell lines (Fig. 3), and that 167 
genes were methylated in at least four cell lines. To identify the 
factors that might influence in their predisposition to DNA meth-
ylation, we compared the occupancy rate of Polycomb proteins 
(EED2 and SUZ12) and the frequency of the H3K27me3 modi-
fication between methylated genes and unmethylated genes in 
HCC cell lines by using the occupancy maps published for em-
bryonic stem cells (27). Genes methylated in HCC cell lines had 
a higher frequency of SUZ12, EED, and H3K27me3 targets com-
pared to genes not methylated in HCC cell lines (Fig. 4). Next, 
we counted the frequency of LINE-1 and ALU in upstream and 
downstream sequences around the transcription start site of 
the 380 genes and then compared the number of LINE-1 or ALU 
repeats between methylated and unmethylated genes in HCC 
cell lines. The number of ALU repeats was significantly higher 
in unmethylated genes than in methylated genes, whereas the 
number of LINE-1 was similar (Fig. 5).
Confirmation of methylation status in HCC tumor tissues
In order to confirm whether CpG island loci methylated in cell 
lines are also methylated in primary tumor tissues, we analyzed 
10 paired HCC and adjacent nonneoplastic liver tissues for their 
methylation status in 239 genes using MSP (Fig. 6). We subdi-
vided all the genes (n = 360) into 6 groups (named 0-5) based on 
the comparison of methylation frequencies of individual genes 
between HCC and nonneoplastic liver tissues: 1) higher meth-
ylation frequency in HCC than in nonneoplastic liver (group 1, 
n = 56), 2) fully methylated in both HCC and non-neoplastic 
liver (group 2, n = 96), 3) not fully methylated but identical meth-
Fig. 3. Methylation-specific 
PCR (MSP) analysis of 380 
selected genes in 8 hepa-
tocellular carcinoma (HCC) 
cell lines. The methylated 
and unmethylated status is 
indicated by a gray and a 
white box, respectively.
Fig. 4. Frequency of H3K27me3 modification and occupancy rate of SUZ12 and EED in methylated (n = 239) and unmethylated genes (n = 141) in human embryonic stem 
cells. The chi-squared test was conducted to analyze the significance of the association. 
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ylation frequencies in HCC and non-neoplastic liver (group 3, 
n = 17), 4) genes not methylated in HCC or non-neoplastic liver 
(group 4, n = 18), 5) genes less frequently methylated in HCC 
than in non-neoplastic livers (group 5, n = 52), and 6) unmeth-
ylated genes in HCC cell lines (group 0, n = 141) (Fig. 6). To iden-
tify key biological functions associated with a list of genes within 
each group, we performed functional annotation analysis using 
the DAVID tool (http://david.abcc.ncifcrf.gov/) (Table 1). Group 1 
genes showed a significant association with the neuropeptide 
signaling pathway, positive regulation of amine transport, and 
acid secretion, whereas group 5 genes exhibited a significant 
association with nucleosome assembly, chromatin assembly, 
protein-DNA complex assembly, chromatin assembly or disas-
sembly, and tissue development.
Correlation of promoter CpG island hypermethylation 
with down-regulation of gene expression
To ensure that the microarray data represent real changes in ex-
Methylated
Unmethylated
Fig. 5. Comparison of ALU and LINE-1 repeats between methylated and unmethyl-
ated genes. For ALU counting, the promoter sequence of a specific gene was divided 
into 20 bins of 1-kb sequence each (10 bins upstream and 10 bins downstream of 
each gene transcription start site), and the presence of ALU was annotated for each 
bin. We counted bins containing ALU within a 1-kb sequence. For LINE-1 counting, 
the promoter sequence of a specific gene was divided into 7 bins of 1-kb sequence 
each (2 bins upstream and 5 bins downstream of each gene transcription site), and 
the presence of LINE-1 was annotated for each bin. Bins containing LINE-1 within a 
1-kb sequence were counted. Student’s t-test was performed to determine the sta-
tistical significance of the difference of means between 2 groups.
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Fig. 6. Methylation-specific PCR (MSP) analysis of 239 genes in 10 pairs of tumor 
and surrounding nontumor tissue. The methylated and unmethylated status is indicat-
ed by a gray and a white box, respectively. Genes were divided into subgroups based 
on the methylation pattern in hepatocellular carcinoma (HCC) tumors and surrounding 
nonneoplastic liver tissues (see main text).
Table 1. Functional annotation analysis of classified genes. Gene ontology of hepatocellular carcinoma (HCC) tumors, surrounding nontumor tissues, and cell lines based on 
their DNA methylation patterns
 Category                                                    Term P value
Group 0 (MF of genes: not methylated in cell lines)
 
Gene expression
Antiapoptosis
Nucleosome assembly
Cellular macromolecule metabolic process
Positive regulation of transmission of nerve impulse
1.E-02
2.E-02
2.E-02
3.E-02
3.E-02
Group 1 (MF of genes: HCC > NL) Neuropeptide signaling pathway
Positive regulation of amine transport
Acid secretion
3.E-02
4.E-02
5.E-02
Group 2 (MF of genes: 100% in both HCC and NL) DNA methylation during gametogenesis
Reproductive process in a multicellular organism
Developmental process
Positive regulation of translation
DNA methylation
3.E-04
8.E-04
2.E-03
4.E-03
4.E-03
Group 3 (MF of genes: HCC = NL) Regulation of steroid metabolic process 3.E-02
Group 5 (MF of genes: HCC < NL) Nucleosome assembly
Chromatin assembly
Protein-DNA complex assembly
Chromatin assembly or disassembly
Tissue development
2.E-03
2.E-03
2.E-03
6.E-03
1.E-02
Group 4: genes did not show any significant association with specific biologic functions. MF, methylation frequency; HCC, hepatocellular carcinoma; NL, normal liver.Jung N, et al.  •  Novel DNA Methylation Markers for Hepatocellular Carcinoma
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Fig. 8. Methylation frequencies of 33 DNA methylation markers in HCC cell lines (n = 8) and tissue samples (10 paired HCC and non-neoplastic liver tissue samples). Methyla-
tion frequencies of these DNA methylation markers in HCC tissue samples were higher than those of non-neoplastic liver tissue samples: the differences were 20% or more.
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more frequently hypermethylated in tumors from patients old-
er than 55 yr than in tumors from patients younger than 55 yr 
(P < 0.05 for all genes). HSPA12B was more frequently methyl-
ated in tumors from female patients than in tumors from male 
patients (P = 0.008). RNASE4 was more frequently methylated 
in tumors smaller than 6 cm than in HCC tumors bigger than 6 
cm (P = 0.018). The methylation frequencies of NETO2, DHDH, 
and SPINT1 were significantly higher in HCC cases with AFP 
production smaller than 100 ng/mL than in HCC cases with AFP 
production higher than 100 ng/mL, whereas the methylation 
frequency of RASGRP2 and HSPA12B was significantly lower in 
HCCs with low AFP production (< 100 ng/mL). INA, PPP1R14A, 
and ECEL1 were more frequently methylated in HCC patients 
with low serum GGT levels (< 56 ng/mL) than in HCC patients 
with high serum GGT levels (≥ 56 ng/mL) (P < 0.05 for all genes). 
The methylation frequencies of C1orf59, OXTR, and CYB5R2 
were significantly lower in HCC tumors with microscopic vein 
invasion than in HCCs without microscopic vein invasion (P <  
0.05 for all genes).
Correlation of DNA methylation markers with clinical 
outcome
Correlation of DNA methylation markers with patient survival 
was analyzed in 90 patients. Five patients were excluded because 
of follow-up loss. Of the 33 CpG loci, HIST1H2AE and EFEMP2 
exhibited an association between gene hypermethylation and 
poor prognosis (P = 0.022 and P = 0.081, respectively, by Kaplan-
Meir log-rank test) (Fig. 10, Table 3). Among several other clini-
copathological factors, tumor size, serum GGT levels, and mi-
croscopic vascular invasion showed prognostic significance. 
Taking into account these 3 clinicopathological factors, HIST-
1H2AE and EFEMP2 were included into a multivariate analysis 
Fig. 10. Kaplan-Meier survival curves of 90 hepatocellular carcinoma (HCC) patients. Correlation of (A) HIST1H2AE, and (B) EFEMP2 methylation status with overall survival.
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pression, we selected 7 genes (CRABP2, EFEMP2, HIST1H2AE, 
INA, NETO2, RASGRP2, and TP53I13) and analyzed their ex-
pression changes in HCC cell lines treated with AZA, TSA, or a 
combination of AZA and TSA using semi-quantitative real-time 
PCR (Fig. 7). Treatment with AZA alone resulted in induction of 
mRNA expression of these 7 genes. In some cases, the effect of 
combined AZA and TSA treatment was stronger than that of AZA 
or TSA alone. These data implicate that histone deacetylation 
may also be involved in the inhibition of gene transcription by 
DNA methylation.
Correlation of DNA methylation markers with 
clinicopathological features of HCC
Genes with methylation frequencies higher in HCC than in non-
neoplastic liver tissues are more likely to play an important role 
in hepatocarcinogenesis. To identify a possible correlation of 
gene hypermethylation with clinicopathological features of HCC 
patients, we selected 33 genes showing a methylation difference 
higher than 19% between HCC and nonneoplastic liver sam-
ples (Fig. 8) and analyzed their methylation statuses in another 
set of HCC tissue samples (n = 95) by MSP. Hypermethylation 
was detected in 1 or more genes in all HCC samples. RNASE4 
showed the highest methylation frequency (90%), followed by 
DUOXA1 (82%), CRABP2 (66%), and NETO2 (61%) (Fig. 9). The 
methylation status of the DNA methylation markers was corre-
lated with clinicopathological features such as age, gender, tu-
mor size, AFP and GGT levels, microscopic vascular invasion, 
and clinical outcome. The results of these association studies 
are summarized in Table 2. The number of methylated genes 
was significantly higher in older (≥ 55 yr) than in younger pa-
tients (11.7 vs 8.8, P = 0.030 by Student’s t-test). NETO2, DHDH, 
MAP6D1, C1orf59, CYB5R2, ULBP1, SPINT1, and ZNF342 were Jung N, et al.  •  Novel DNA Methylation Markers for Hepatocellular Carcinoma
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to identify independent predictors of overall survival (Table 4). 
Multivariate analysis by using the COX proportional hazards 
model revealed that HIST1H2AE (P = 0.010) and EFEMP2 (P =  
0.020) methylation status are significant variables affecting the 
overall survival of HCC patients. The methylation status of these 
two genes suggested about 2.6-fold increased risk as compared 
to patients who had these genes unmethylated.
DISCUSSION
In this study, we conducted a genome-wide microarray expres-
sion screening in 5 HCC cell lines treated with AZA or TSA and 
characterized a set of methylation-regulated genes. We were able 
to identify 221 novel DNA methylation markers in HCC. At the 
same time, we observed that a significant number of genes up-
regulated after AZA treatment, were actually not methylated in 
HCC cell lines and primary HCC tissue samples. While the mech-
anisms by which AZA reactivates expression of unmethylated 
genes has not been elucidated yet, several possibilities exist. 
First, the up-regulation of unmethylated genes might be second-
ary to AZA-induced expression of upstream genes that encode 
transcription factors and are inactivated by promoter CpG island 
hypermethylation, Second, the expression of these genes might 
be regulated by the methylation status of CpG island shores rather 
than promoter CpG islands (28). Lastly, AZA might induce deg-
radation of retinoblastoma protein (pRb) through the MDM2-
dependent proteasome pathway. Because loss of pRb protein in-
duces a significant decrease in recruitment of G9a and SUV39H1 
to histones around the promoter of target genes and thus re-
duced H3K9 di- and tri-methylation, pRb degradation might 
result in re-expression of several silenced genes (Dr. Wei-Guo 
Zhu, personal communication).
  In the present study, of the 380 genes containing CpG island 
loci in their promoter sequences and for which MSP oligonu-
cleotide primers could be designed, 239 genes were found to be 
methylated in at least 1 HCC cell line. The remaining genes were 
found to be unmethylated in all HCC cell lines. The causes of 
selective predisposition to methylation are at present unclear. 
However, genome architecture has been recently proposed to 
strongly correlate with predisposition to DNA methylation. Spe-
cifically, genes with low frequency of retrotransposons (ALU and 
LINE-1) near the transcription start site or regulated by Poly-
comb-group protein binding are more prone to DNA methyla-
tion (29, 30). When we matched these data with ours, we also 
could observe that ALU and Polycomb-group proteins were sig-
nificantly correlated with methylated status, whereas LINE-1 
was not.
  We analyzed 95 HCC samples for their methylation status in 
33 CpG island loci and found that HCC tumors from older pa-
tients harbored more methylated genes than HCC tumors from 
younger patients. In addition, we found that 2 DNA methylation 
markers (HIST1H2AE and EFEMP2) are closely associated with 
poor prognosis of HCC patients. HIST1H2AE is a member of the 
histone H2A family. Histones are responsible for nucleosome 
structure and their appropriate balance is required for the cor-
rect assembly of chromatin as well as for proper cell division 
and growth (31, 32). H2a, one of the core histones, has nonalle-
lic variants that are related by simple amino acid substitution 
(33). It is not clear whether these variants have functional signif-
Table 3. Univariable analysis of clinicopathological characteristics with regard to sur-
vival of hepatocellular carcinoma (HCC) patients. The P value was determined by the 
Kaplan-Meier method
Characteristics 
No. of  
patients
3-yr  
survival  
rate (%)
5-yr  
survival  
rate (%)
P value
Sex
   M
   F
 
71
19
 
56
45
 
43
45
0.782
 
Age (yr)
   < 55 
   ≥ 55 
 
44
46
 
41
66
 
33
53
0.014
 
Tumor size (cm)
   < 6 
   ≥ 6 
 
41
47
 
72
38
 
61
28
< 0.001
 
Background liver
   Cirrhosis
   Chronic hepatitis
 
60
30
 
46
69
 
35
60
0.037
 
Child-Pugh score
   A
   B
   C
 
81
  9
  0
 
57
27
-
 
47
14
-
0.136
 
 
GGT (IU/L)
   < 56 
   > 56 
 
44
46
 
65
44
 
59
30
0.012
 
Microscopic invasion
   Absent
   Present
 
37
51
 
68
46
 
60
33
0.014
 
HIST1H2AE
   Unmethylated
   Methylated
 
76
14
 
57
35
 
47
26
0.022
 
EFEMP2 
   Unmethylated
   Methylated
 
77
13
 
58
31
 
45
31
0.080
 
Histologic grade
(Edmondson-Steiner)
   1, 2
   3, 4
 
52
23
 
60
44
 
45
44
0.408
 
AFP (ng/mL)
   < 100 
   > 100 
 
47
39
 
59
46
 
50
32
0.091
Table 4. Multivariate analysis of factors associated with poor survival in HCC patients
β SE
Hazard ratio
(95% confidence interval)
P value
Tumor size 0.913 0.359 2.491 (1.231-5.037) 0.011
GGT 0.746 0.328 2.109 (1.109-4.012) 0.023
Microscopic vascular 
   invasion
0.668 0.359 1.951 (0.966-3.941) 0.062
EFEMP2 methylation 0.962 0.413 2.618 (1.166-5.878) 0.020
HIST1H2AE methylation 0.982 0.380 2.670 (1.268-5.624) 0.010Jung N, et al.  •  Novel DNA Methylation Markers for Hepatocellular Carcinoma
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icance and how the expression of individual histone genes is 
controlled. Among the 16 replication-dependent histone H2a 
genes, HIST1H2AE is included in the largest histone gene clus-
ter (HIST1, including 55 histone genes) located on human chro-
mosome 6 (34, 35). Previous studies have found that the expres-
sion of histone H2a genes is related to histone gene clusters with 
different promoters and different transcription factor binding 
sites in mouse hepatoma cell lines. However, the structure in 
the promoters and transcription binding sites responsible for 
such differential expression has not been determined yet. On 
the other hand, it has been reported that the H2a genes are reg-
ulated by histone H3K9 acetylation levels in the promoter re-
gions (36). Similarly, we suggest that HIST1H2AE transcription 
might be influenced by histone acetylation based on the exper-
imental results obtained by RT-PCR, using AZA-, TSA- or com-
bined AZA/TSA-treated cell lines. The combinatory treatment 
showed to act synergistically in the reexpression of HIST1H2AE.
  EFEMP2, also known as fibulin-4, is a novel extracellular ma-
trix protein that belongs to the fibulin protein family (fibulin1-7). 
EFEMP2 is involved in the stabilization and organization of the 
extracellular matrix. Moreover, missense mutations of EFEMP2 
(G169A) cause human genetic disorders (37-39). However, the 
role of EFEMP2 in driving tumorigenesis is still unclear and re-
quires further study. A recent study has reported limited EFEMP2 
methylation in melanoma cell lines (40). In contrast, our data 
have demonstrated a correlation of its methylation status with 
poor survival of HCC patients. 
  In conclusion, we have identified 221 novel DNA methyla-
tion markers for HCC by using a pharmacological unmasking 
microarray approach along with MSP. Of these, 55 DNA meth-
ylation markers are more frequently methylated in HCC than in 
adjacent nonneoplastic liver tissues. The biological functions of 
these genes are associated with neuropeptide signaling pathways 
and positive regulation of amine transport. HIST1H2AE meth-
ylation is strongly associated with poor prognosis of HCC pa-
tients. A future independent study is required to validate HIST-
1H2AE methylation as a prognostic marker for HCC.
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